Bortezomib-induced Sweet syndrome.
Knoops
Laurent
L
Department of Haematology, Cliniques Universitaires Saint-Luc, Catholic University of Louvain, Brussels, Belgium. laurent.knoops@bru.licr.org
Jacquemain
Aurore
A
Tennstedt
Dominique
D
Theate
Ivan
I
Ferrant
Augustin
A
Van den Neste
Eric
E
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001897:Boronic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D000069286:Bortezomib; D003875:Drug Eruptions / Q000209:etiology*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use; D016463:Sweet Syndrome / Q000139:chemically induced*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D005938:Glucocorticoids; D011719:Pyrazines; D000069286:Bortezomib; D008775:Methylprednisolone